Liver cancer understaging in liver transplantation in the current era of radiologic imaging and newer generation locoregional therapies

Abstract

Background: Discordance in hepatocellular carcinoma (HCC) staging between pre-transplant imaging and explant pathology is associated with an increased risk of recurrence and death. Our aim was to evaluate variables that predicted concordance/discordance in the era of new generation locoregional therapies (LRT) and improved radiologic technology in diagnosis.

Methods: A single-center retrospective study was performed on patients who received a liver transplant for HCC between 2008-2019. Pre- and post-LT variables, including type of LRT, downstaging (DS), transplant time period, and radiologic response to LRT, were analyzed for concordance/discordance. Kaplan-Meier analysis was used to assess post-LT survival.

Results: Of 146 patients transplanted within Milan Criteria (MC), discordance rates (understaged) were 45%. Discordance was associated with ≥ 3 HCC lesions at diagnosis but not newer generation LRT (transarterial radioembolization/ stereotactic body radiation therapy), traditional LRT or combination. No differences in discordance were seen between transplant periods (2008-2013 vs. 2014-2019), but those within MC in the earlier period had higher concordance rates. A trend was observed between DS and discordance.

Conclusion: HCC stage discordance remains common and poorly predictable. Discordance was associated with three or more HCC lesions at the time of diagnosis. Patients within MC transplanted between 2008-2013 was associated with concordance, while a trend was noted between DS and discordance. No other pre- or post- LT variables predicted discordance/ concordance. Discordance was associated with decreased survival.

Keywords

Hepatocellular carcinoma / understaging / liver transplant / radioembolization / stereotactic body radiation therapy (SBRT)

References

[1] Mazzaferro V,Doci R.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med1996;334:693-9

[2] Freeman RB,Harper AM.Waiting list removal rates among patients with chronic and malignant liver diseases.Am J Transplant2006;6:1416-21

[3] Ecker BL,Forde KA.Patterns of discordance between pretransplant imaging stage of hepatocellular carcinoma and posttransplant pathologic stage: a contemporary appraisal of the milan criteria.Transplantation2018;102:648-55

[4] Duffy JP,Benjamin E.Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.Ann Surg2007;246:502-9;discussion 509 PMCID:PMC1959350

[5] Mahmud N,Goldberg DS.Risk factors and center-level variation in hepatocellular carcinoma under-staging for liver transplantation.Liver Transpl2020;26:977-88 PMCID:PMC7897468

[6] Mehta N,Grab JD.National experience on down-staging of hepatocellular carcinoma before liver transplant: influence of tumor burden, alpha-fetoprotein, and wait time.Hepatology2020;71:943-54 PMCID:PMC8722406

[7] Salem R,Mulcahy MF.Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.Gastroenterology2010;138:52-64

[8] Zori AG,Limaye AR.Locoregional therapy protocols with and without radioembolization for hepatocellular carcinoma as bridge to liver transplantation.Am J Clin Oncol2020;43:325-33

[9] Gabr A,Mouli S.Liver Transplantation following yttrium-90 radioembolization: 15-year experience in 207-patient cohort.Hepatology2021;73:998-1010

[10] Katz AW,Qu Z,Milano MT.Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation.Int J Radiat Oncol Biol Phys2012;83:895-900

[11] O'Connor JK,Davis GL,Klintmalm GB.Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation.Liver Transpl2012;18:949-54

[12] Mohamed M,Tejani MA.Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma.Adv Radiat Oncol2016;1:35-42 PMCID:PMC5506745

[13] Murray LJ.Advances in stereotactic body radiation therapy for hepatocellular carcinoma.Semin Radiat Oncol2017;27:247-55

[14] Bharwani N.Diffusion-weighted imaging of the liver: an update.Cancer Imaging2013;13:171-85 PMCID:PMC3629892

[15] Yuan Z,Yang H,Xu LC.Diffusion-weighted MR imaging of hepatocellular carcinoma: current value in clinical evaluation of tumor response to locoregional treatment.J Vasc Interv Radiol2016;27:20-30;quiz 31

[16] Liver Reporting & Data System (LI-RADS). Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS [Last accessed on 18 Apr 2022]